These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23118218)

  • 21. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
    Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
    Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.
    Enzler T; Kater AP; Zhang W; Widhopf GF; Chuang HY; Lee J; Avery E; Croce CM; Karin M; Kipps TJ
    Blood; 2009 Nov; 114(20):4469-76. PubMed ID: 19755673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
    Hanna BS; McClanahan F; Yazdanparast H; Zaborsky N; Kalter V; Rößner PM; Benner A; Dürr C; Egle A; Gribben JG; Lichter P; Seiffert M
    Leukemia; 2016 Mar; 30(3):570-9. PubMed ID: 26522085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
    McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
    Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons learned from the Eµ-TCL1 mouse model of CLL.
    Floerchinger A; Seiffert M
    Semin Hematol; 2024 Jun; 61(3):194-200. PubMed ID: 38839457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase.
    Kleemann R; Kapurniotu A; Frank RW; Gessner A; Mischke R; Flieger O; Jüttner S; Brunner H; Bernhagen J
    J Mol Biol; 1998 Jul; 280(1):85-102. PubMed ID: 9653033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.
    Galletti G; Scielzo C; Barbaglio F; Rodriguez TV; Riba M; Lazarevic D; Cittaro D; Simonetti G; Ranghetti P; Scarfò L; Ponzoni M; Rocchi M; Corti A; Anselmo A; van Rooijen N; Klein C; Ries CH; Ghia P; De Palma M; Caligaris-Cappio F; Bertilaccio MTS
    Cell Rep; 2016 Feb; 14(7):1748-1760. PubMed ID: 26876171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.
    Alhakeem SS; McKenna MK; Oben KZ; Noothi SK; Rivas JR; Hildebrandt GC; Fleischman RA; Rangnekar VM; Muthusamy N; Bondada S
    J Immunol; 2018 Jun; 200(12):4180-4189. PubMed ID: 29712773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Host derived macrophage migration inhibitory factor expression attenuates anti-tumoral immune cell accumulation and promotes immunosuppression in the tumor microenvironment of head and neck squamous cell carcinoma.
    Ryan N; Lamenza F; Shrestha S; Upadhaya P; Springer A; Jordanides P; Pracha H; Roth P; Kumar R; Wang Y; Vilgelm AE; Satoskar A; Oghumu S
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167345. PubMed ID: 38992847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of macrophage migration inhibitory factor in the Th2 immune response to epicutaneous sensitization.
    Das R; Moss JE; Robinson E; Roberts S; Levy R; Mizue Y; Leng L; McDonald C; Tigelaar RE; Herrick CA; Bucala R
    J Clin Immunol; 2011 Aug; 31(4):666-80. PubMed ID: 21559932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease.
    Chen L; Zhou X; Fan LX; Yao Y; Swenson-Fields KI; Gadjeva M; Wallace DP; Peters DJ; Yu A; Grantham JJ; Li X
    J Clin Invest; 2015 Jun; 125(6):2399-412. PubMed ID: 25961459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macrophage migration inhibitory factor (MIF) and pregnancy may impact the balance of intestinal cytokines and the development of intestinal pathology caused by Toxoplasma gondii infection.
    Marcon CF; Ferreira PTM; Franco PS; Ribeiro M; Silva RJ; Sousa RAP; Oliveira CJF; Rodrigues Junior V; Gomes MLM; Lazo Chica JE; Mineo TWP; Mineo JR; Barbosa BF; Ferro EAV; Gomes AO
    Cytokine; 2020 Dec; 136():155283. PubMed ID: 32947151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EOMES is essential for antitumor activity of CD8
    Llaó-Cid L; Roessner PM; Chapaprieta V; Öztürk S; Roider T; Bordas M; Izcue A; Colomer D; Dietrich S; Stilgenbauer S; Hanna B; Martín-Subero JI; Seiffert M
    Leukemia; 2021 Nov; 35(11):3152-3162. PubMed ID: 33731848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
    Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
    Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
    Gassner FJ; Zaborsky N; Catakovic K; Rebhandl S; Huemer M; Egle A; Hartmann TN; Greil R; Geisberger R
    Br J Haematol; 2015 Aug; 170(4):515-22. PubMed ID: 25940792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia.
    Fedorchenko O; Stiefelhagen M; Peer-Zada AA; Barthel R; Mayer P; Eckei L; Breuer A; Crispatzu G; Rosen N; Landwehr T; Lilienthal N; Möllmann M; Montesinos-Rongen M; Heukamp L; Dürig J; Hallek M; Fingerle-Rowson G; Herling M
    Blood; 2013 May; 121(20):4126-36. PubMed ID: 23547049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
    Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
    Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of macrophage migration inhibitory factor reduces proliferative retinopathy in a mouse model.
    Wang J; Lin J; Kaiser U; Wohlfart P; Hammes HP
    Acta Diabetol; 2017 Apr; 54(4):383-392. PubMed ID: 28070752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling.
    Klasen C; Ohl K; Sternkopf M; Shachar I; Schmitz C; Heussen N; Hobeika E; Levit-Zerdoun E; Tenbrock K; Reth M; Bernhagen J; El Bounkari O
    J Immunol; 2014 Jun; 192(11):5273-84. PubMed ID: 24760155
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Bezdek S; Leng L; Busch H; Mousavi S; Rades D; Dahlke M; Zillikens D; Bucala R; Sadik CD
    Front Immunol; 2018; 9():2262. PubMed ID: 30333830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.